Talley Rw
Impact in
-
- Cancer Treatment and Pharmacology
- Metal complexes synthesis and properties
- Lung Cancer Research Studies
-
- Lymphoma Diagnosis and Treatment
- Chemotherapy-induced organ toxicity mitigation
Papers in
- Oncology 8
- Cancer Treatment and Pharmacology 4
- Colorectal Cancer Treatments and Studies 3
- Lung Cancer Research Studies 2
-
- Lung Cancer Treatments and Mutations 3
- Sarcoma Diagnosis and Treatment 1
- Co-authors
- Tate Thigpen (1 shared paper)C. W. Groppe (1 shared paper)R I Fisher (1 shared paper)Baker Lh (3 shared papers)Jones Se (1 shared paper)Coltman Ca (1 shared paper)Emil Frei (1 shared paper)Bethan McDonald (2 shared papers)
- Journals
- PubMed (24 papers)
- Partner nations
- United States
In The Last Decade
Talley Rw
22 papers receiving 294 citations
Peers
Comparison fields: 5 of 64
- Oncology 160
- Pathology and Forensic Medicine 62
- Pulmonary and Respiratory Medicine 75
- Cardiology and Cardiovascular Medicine 45
- Neurology 30
Countries citing papers authored by Talley Rw
This map shows the geographic impact of Talley Rw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Talley Rw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Talley Rw more than expected).
Fields of papers citing papers by Talley Rw
This network shows the impact of papers produced by Talley Rw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Talley Rw. The network helps show where Talley Rw may publish in the future.
Co-authors
The 18 scholars most cited alongside Talley Rw, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875)--phase I clinical study. | 1974 | 82 |
| 2 | Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388). | 1970 | 58 |
| 3 | Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study. | 1980 | 54 |
| 4 | 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of lymphoma. | 1972 | 22 |
| 5 | Phase II evaluation of cis-dichlorodiammineplatinum(II) in lymphomas: a Southwest Oncology Group Study. | 1980 | 19 |
| 6 | Critical analysis of the control of malignant effusions with radioisotopes. | 1968 | 18 |
| 7 | Phase II study of AMSA in lung cancer. | 1981 | 17 |
| 8 | Phase I--II study of intermittent bolus administration of DTIC and actinomycin D in metastatic malignant melanoma. | 1978 | 11 |
| 9 | Preliminary trials with combination therapy of cyclophosphamide (NSC-26271), vincristine (NSC-67574), and 5-fluorouracil (NSC-19893). | 1968 | 7 |
| 10 | Pheochromocytoma: current concepts. | 1967 | 6 |
| 11 | Phase II trial of mitoxantrone in previously untreated patients with colorectal adenocarcinoma: A Southwest Oncology Group Study. | 1982 | 5 |
| 12 | The clinical use of fluorine18 in bone scanning. | 1969 | 5 |
| 13 | Porfiromycin in the management of epidermoid and transitional cell cancer: a phase II study. | 1976 | 4 |
| 14 | Combination chemotherapy with mitomycin C, adriamycin, and cyclophosphamide in advanced adenocarcinoma and large cell carcinoma of the lung. | 1980 | 3 |
| 15 | Treatment of adenocarcinoma with combinations of cyclopjosphamide (NSC-26271), vincristine (NSC-67574), and 5-fluorouracil (NSC-19893). | 1975 | 3 |
| 16 | Clinical evaluation of 1,3-bis(2-chloroethyl)-nitrosourea (BCNU; NSC-409962) with fluoxymesterone (NSC-12165) in the treatment of solid tumors. | 1973 | 3 |
| 17 | Guanazole (NSC-1895)--a phase I clinical study. | 1976 | 3 |
| 18 | Phase II trial of amsacrine in metastatic or locally recurrent squamous cell carcinoma from head and neck primaries: a Southwest Oncology Group study. | 1984 | 2 |
| 19 | Chemotherapy of advanced ovarian cancer. | 1961 | 2 |
| 20 | Investigational and practical chemotherapy of solid tumors. | 1970 | 2 |
About Talley Rw
Talley Rw is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Organic Chemistry, Molecular Biology and Cancer Research, having authored 24 papers that have together received 332 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (4 papers), Colorectal Cancer Treatments and Studies (3 papers), Lung Cancer Treatments and Mutations (3 papers), Lung Cancer Research Studies (2 papers), Cancer therapeutics and mechanisms (2 papers), Beetle Biology and Toxicology Studies (2 papers), Cancer and Skin Lesions (2 papers) and Sarcoma Diagnosis and Treatment (1 paper). The work is most often cited by research in Oncology (160 citations), Pathology and Forensic Medicine (62 citations), Pulmonary and Respiratory Medicine (75 citations), Cardiology and Cardiovascular Medicine (45 citations) and Neurology (30 citations). Talley Rw has collaborated with scholars based in United States. Frequent co-authors include Tate Thigpen, C. W. Groppe, R I Fisher, Baker Lh, Jones Se, Coltman Ca, Emil Frei, Bethan McDonald, Glenn Cummings and Von Hoff. Their work appears in journals such as PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.